Using E-Nose Technology to Track Treatment Response in People With Non-Small Cell Lung Cancer
Recruiting
Phase 2
Interventional Study
Non-Small Cell Lung Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 60 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure changes in certain chemicals in the breath before and after standard neoadjuvant therapy in people with NSCLC.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age ≥18
* Untreated clinical stage I NSCLC amenable to upfront surgery
* Untreated stage II to IIIB NSCLC amenable to neoadjuvant treatment followed by surgery
* ECOG Performance Status of ≤2 Of note, the E-nose is a completely noninvasive technology (only breath samples are c…
Contacts
David Jones, MD
212-639-6428
CONTACT